WREN LABORATORIES LIMITED
Get an alert when WREN LABORATORIES LIMITED files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Next accounts due
2026-12-31 (in 7mo)
Last filed for 2025-03-31
Confirmation statement due
2027-04-19 (in 11mo)
Last made up 2026-04-05
Watchouts
None on the register
Cash
£1M
+39.6% vs 2024
Net assets
£1M
+13.6% vs 2024
Employees
101
-1% vs 2024
Profit before tax
£2M
+524.9% highest in 4 filed years
Net assets
4-year trend · vs Consumer Discretionary median
Accounts
4-year trend · latest reflected 2025-03-31
| Metric | Trend | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 |
|---|---|---|---|---|---|
| Turnover | — | — | £10,247,184 | £12,888,514 | |
| Operating profit | — | — | £318,943 | £1,338,420 | |
| Profit before tax | £304,054 | £772,653 | £320,570 | £2,003,307 | |
| Net profit | £248,573 | £640,209 | £240,583 | £1,665,807 | |
| Cash | £1,619,208 | £491,003 | £752,629 | £1,050,564 | |
| Total assets less current liabilities | £2,631,775 | £3,271,984 | £1,262,912 | £1,428,374 | |
| Net assets | £2,591,775 | £3,231,984 | £1,222,567 | £1,388,374 | |
| Equity | £2,591,775 | £3,231,984 | £1,222,567 | £1,388,374 | |
| Average employees | 78 | 85 | 102 | 101 | |
| Wages | £2,465,106 | £3,027,114 | £3,306,017 | £3,451,103 | |
| Directors' remuneration | — | — | £37,634 | £48,424 |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers
Year-on-year
FY2024 → FY2025 · period ending 2025-03-31 vs 2024-03-31
-
Turnover
+25.8%
£10,247,184 £12,888,514
-
Cash
+39.6%
£752,629 £1,050,564
-
Net assets
+13.6%
£1,222,567 £1,388,374
-
Employees
-1%
102 101
-
Operating profit
+319.6%
£318,943 £1,338,420
-
Profit before tax
+524.9%
£320,570 £2,003,307
highest in 4 filed years
-
Wages
+4.4%
£3,306,017 £3,451,103
highest in 4 filed years
Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 |
|---|---|---|---|---|---|
| Operating margin | — | — | 3.1% | 10.4% | |
| Net margin | — | — | 2.3% | 12.9% | |
| Return on capital employed | — | — | 25.3% | 93.7% | |
| Gearing (liabilities / total assets) | — | — | 77.6% | 81.9% | |
| Current ratio | — | — | 1.26x | 1.04x | |
| Interest cover | — | — | — | 131.10x |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Name history
Renamed 2 times since incorporation
- WREN LABORATORIES LIMITED 2005-02-01 → present
- WREN DIAGNOSTICS LIMITED 2004-06-03 → 2005-02-01
- RIDGEWAY DIAGNOSTICS LIMITED 2004-04-05 → 2004-06-03
Audit & accounting basis
- Accounting basis
- FRS 102
- Reporting scope
- Standalone (parent only)
- Auditor
- Old Mill Audit Limited
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate. Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.”
Group structure
- WREN LABORATORIES LIMITED · parent
- Optibac Probiotics (Vietnam) Limited 100%
- Medipharma Limited 100%
Significant events
- “This financial year saw an update to the Optibac packaging. The new look and feel aligns with Optibac's mission to provide premium and scientifically backed probiotics to as many people as possible.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
5 active · 1 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| MATCHAM, Debbie | Secretary | 2004-04-05 | — | British |
| JANMOHAMED, Farah | Director | 2017-11-08 | Jul 1987 | British |
| JANMOHAMED, Feroze Issa Ismail | Director | 2004-04-05 | Dec 1946 | British |
| JANMOHAMED, Jalal | Director | 2005-10-03 | Sep 1982 | British |
| JANMOHAMED, Soraya | Director | 2017-11-08 | Mar 1986 | British |
Show 1 resigned officer
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| KHUBCHANDANI, Rishi Richie | Director | 2005-10-03 | 2010-03-10 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Medipharma Group Limited | Corporate entity | Shares 75–100%, Voting 75–100% | 2018-09-04 | Active |
| Mr Feroze Issa Ismail Janmohamed | Individual | Shares 25–50% | 2016-04-06 | Ceased 2018-09-04 |
| Mr Jalal Janmohamed | Individual | Shares 25–50% | 2016-04-06 | Ceased 2018-09-04 |
Filing timeline
Last 20 of 76 total filings
Material constitutional events — rename, articles re-file, resolution
- 2025-12-31 MA Memorandum articles
- 2025-12-31 RESOLUTIONS Resolution
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2026-04-08 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2025-12-31 | MA | incorporation | Memorandum articles | |
| 2025-12-31 | RESOLUTIONS | resolution | Resolution | |
| 2025-12-22 | SH01 | capital | Capital allotment shares | |
| 2025-12-16 | AA | accounts | Accounts with accounts type full | |
| 2025-04-16 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2024-10-30 | AA | accounts | Accounts with accounts type full | |
| 2024-04-16 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2024-04-16 | CH01 | officers | Change person director company with change date | |
| 2023-12-21 | AA | accounts | Accounts with accounts type full | |
| 2023-04-06 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2023-03-24 | AA | accounts | Accounts with accounts type full | |
| 2022-04-28 | CH01 | officers | Change person director company with change date | |
| 2022-04-05 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2022-04-04 | AA | accounts | Accounts with accounts type full | |
| 2021-04-06 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2021-03-22 | AA | accounts | Accounts with accounts type total exemption full | |
| 2020-04-07 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2019-12-16 | AA | accounts | Accounts with accounts type total exemption full | |
| 2019-04-09 | CS01 | confirmation-statement | Confirmation statement with updates |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 5
- Capital events
- 1
- Officers appointed
- 0
- Officers resigned
- 0
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.